Amarin Corp Plc (AMRN)

[KCSVEN]

Epanova a little late to the party, Anchor will be well established and as we have seen with Vascepa failing to take away Lovaza market share in droves once people are on something working they don't switch easily.

Again, seems like Vascepa has timed entry to market pretty well and by time any competitor gets to have a sniff of entering Anchor market Reduce It will be out ending all discussion on which drug to prescribe if positive result.

Just don't see Epanova as a material competitor to Vascepa